Literature DB >> 16957152

ERCC1 measurements in clinical oncology.

Eddie Reed.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16957152     DOI： 10.1056/NEJMe068162

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA.

Authors:  Oleg V Tsodikov; Dmitri Ivanov; Barbara Orelli; Lidija Staresincic; Ilana Shoshani; Robert Oberman; Orlando D Schärer; Gerhard Wagner; Tom Ellenberger
Journal:  EMBO J       Date:  2007-10-18       Impact factor: 11.598

2.  First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure.

Authors:  Nicolaas G J Jaspers; Anja Raams; Margherita Cirillo Silengo; Nils Wijgers; Laura J Niedernhofer; Andria Rasile Robinson; Giuseppina Giglia-Mari; Deborah Hoogstraten; Wim J Kleijer; Jan H J Hoeijmakers; Wim Vermeulen
Journal:  Am J Hum Genet       Date:  2007-01-29       Impact factor: 11.025

3.  Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1.

Authors:  Rui Gao; Douglas K Price; Tristan Sissung; Eddie Reed; William D Figg
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

Review 4.  Developing precision medicine in a global world.

Authors:  Eric H Rubin; Jeffrey D Allen; Jan A Nowak; Susan E Bates
Journal:  Clin Cancer Res       Date:  2014-03-15       Impact factor: 12.531

5.  Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.

Authors:  Sanjeevani Arora; Anbarasi Kothandapani; Kristin Tillison; Vivian Kalman-Maltese; Steve M Patrick
Journal:  DNA Repair (Amst)       Date:  2010-04-24

6.  Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer.

Authors:  Jeffrey G Schneider; Nosha Farhadfar; Abirami Sivapiragasam; Matthew Geller; Shahidul Islam; Elena Selbs
Journal:  Oncologist       Date:  2014-04-04

7.  Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.

Authors:  Dimitra T Stefanou; Aristotelis Bamias; Hara Episkopou; Soterios A Kyrtopoulos; Maria Likka; Theodore Kalampokas; Stylianos Photiou; Nikos Gavalas; Petros P Sfikakis; Meletios A Dimopoulos; Vassilis L Souliotis
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

8.  β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK.

Authors:  Quentin Q Li; Rebecca X Lee; Huasheng Liang; Gangduo Wang; Jueli M Li; Yuhua Zhong; Eddie Reed
Journal:  Int J Oncol       Date:  2013-06-28       Impact factor: 5.650

9.  GLI1 upregulates C-JUN through a specific 130-kDa isoform.

Authors:  Lauren Amable; Elaine Gavin; Kenji Kudo; Erhong Meng; Rodney P Rocconi; Lalita A Shevde; Eddie Reed
Journal:  Int J Oncol       Date:  2013-12-20       Impact factor: 5.650
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.